BTK inhibitors offer a new paradigm for the treatment of autoimmune diseases and AIBD in particular, with pemphigus having the most compelling unmet need, since they potentially act much faster via the innate immune system, compared with rituximab. Here, BTK is linked to autoimmune disease.